"Millions of women are struggling to access essential estradiol patches for menopause symptom relief, yet the federal drug shortage list remains conspicuously empty, leaving patients and providers grappling with inconsistent supply and the implications of a formal designation."
Federal regulators have acknowledged the widespread difficulty women are experiencing in obtaining estradiol transdermal patches, a cornerstone of hormone replacement therapy for millions of Americans managing menopause symptoms. Despite months of reports from patients unable to reliably fill prescriptions, the U.S. Food and Drug Administration (FDA) has not officially added these critical medications to its drug shortage list. This discrepancy between the lived experience of patients and the official federal designation is at the heart of growing frustration among healthcare providers and advocates, highlighting a gap that can have significant consequences for patient care and access to necessary treatments.
The FDA, in an update on September 3, recognized that increased demand has led to accessibility challenges for certain estradiol patch products. The agency noted that availability can vary significantly by pharmacy and geographic location, though it maintained that estradiol patches, in general, remain available. In an effort to underscore the administration’s commitment to addressing the issue, the FDA stated that the supply of FDA-approved estradiol patches has nearly doubled over the past year. Manufacturers are reportedly responding by increasing production, extending operating hours, expanding manufacturing capacity, increasing batch sizes, investing in specialized equipment and production lines, and prioritizing patch manufacturing.
However, the crucial point of contention remains the absence of estradiol patches from the FDA’s formal drug shortage list. This official designation is far more than a symbolic label; it carries substantial weight in the pharmaceutical supply chain. A formal shortage listing can unlock regulatory flexibility for manufacturers, provide a clear signal to suppliers and prescribers about the severity of the situation, and direct agency resources towards identifying and mitigating the root causes of the supply disruptions.
The divergence between the FDA’s assessment and the reality on the ground is starkly illustrated by the American Society of Health-System Pharmacists (ASHP). ASHP, a leading professional organization that collects reports from pharmacists, healthcare providers, and patients, currently lists more than a dozen estradiol patch products on its active drug shortage list. In contrast, the FDA’s own public drug shortage database does not reflect this widespread scarcity. This disparity has become a significant source of frustration for clinicians who are on the front lines, attempting to manage patient care amidst unpredictable availability.
Clinicians specializing in women’s health have been observing this pattern for months, with menopause clinics reporting consistent difficulties since the winter. Dr. Rajita Patil, director of UCLA Health’s Comprehensive Menopause Program, has witnessed a sharp increase in demand for these therapies over the past three to four years, telling NBC News, "I don’t think that the supply chain was ready for that." This sentiment is echoed by many in the medical community, who feel that the existing manufacturing infrastructure has been outpaced by evolving patient needs and treatment trends.
In response to the ongoing challenges, Dr. Suzanne Hackenmiller, an obstetrician-gynecologist in Arizona, has launched a petition urging the FDA to formally declare a shortage of estradiol patches. Dr. Hackenmiller believes that such a declaration would provide a critical incentive for current manufacturers to significantly ramp up production and could also encourage new companies to enter the market, thereby increasing overall supply. She emphasized the vital role these medications play, describing them as "medically necessary medications that are preventing disease in women after menopause."
The call for formal recognition of the shortage has also been amplified by a group of Democratic members of the U.S. House of Representatives. These lawmakers have urged the FDA to add estradiol patches to the federal shortage database. In a formal letter, they argued that the FDA’s reliance on historical demand data for assessing manufacturing pace might not accurately reflect situations where demand has surged rapidly. This lag in data interpretation could contribute to the delay in recognizing and formally addressing the shortage. CBS News reported that the FDA did not provide a comment regarding this request prior to its September update.
The FDA, in its public statements, has framed the rising demand for estradiol patches as a positive development for women’s health, indicating that it is working collaboratively with manufacturers to ensure continued supply. While both the acknowledgment of increased demand and the efforts to boost production may be accurate, the agency’s perspective does not fully reconcile with the experience of pharmacies struggling to meet immediate patient needs. A product can be manufactured at its maximum capacity and still be unavailable at a specific pharmacy on a given day due to logistical hurdles, distribution issues, or fluctuating local demand.
The recent surge in demand for estradiol patches is directly traceable to a significant policy change implemented by the FDA in November 2025. At that time, the agency requested that manufacturers revise the labeling for menopausal hormone therapy products to remove boxed warnings that previously highlighted a probable increased risk of breast cancer, cardiovascular disease, and probable dementia. The FDA stated that this labeling change provided women and their healthcare providers with updated information to engage in more individualized discussions about the benefits and risks associated with hormone therapy. This regulatory action followed two decades during which these prominent warnings had significantly discouraged both the prescribing and use of menopausal hormone therapies.
The impact of this labeling change on prescribing patterns was swift and substantial. According to nationwide data from the health technology company HealthVerity, cited by CBS News, prescriptions for estrogen patches increased dramatically from approximately 594,000 in June 2024 to 1.6 million in May 2026. A separate analysis conducted by Epic Research, which examines electronic health records, revealed an 86 percent increase in hormone therapy prescriptions for women aged 50 to 65 since 2021.
However, the supply side of the equation did not scale at the same pace, a challenge rooted in the inherent complexities of pharmaceutical manufacturing rather than a lack of willingness from manufacturers. The FDA itself points out that the production of transdermal patches requires specialized equipment and intricate manufacturing processes. Consequently, significant expansions in manufacturing capacity can take considerable time, even when companies are committed to increasing output. This manufacturing lead time creates a natural lag between a surge in demand and the ability of the supply chain to fully meet it.
The burden of this supply-demand imbalance is most acutely felt by households attempting to navigate the daily logistics of obtaining their medication. Diane Harris, a mother of three in Los Angeles who relies on a twice-weekly estradiol patch, shared her experience with CBS News. She recounted calling numerous pharmacies, attempting to ration her existing patches when she couldn’t secure a consistent supply, and ultimately having to travel more than 25 miles to a pharmacy that could fill her prescription. This situation highlights the significant inconvenience and potential disruption to daily life that patients are facing.
The cost implications of the shortage represent a second layer of burden for patients. Dr. Hackenmiller noted that some patients who would typically receive a 90-day supply of their medication are now being issued only 30-day supplies due to pharmacy stock limitations. This means that instead of paying a single co-pay for a three-month supply, patients may find themselves paying the co-pay three times within the same period, significantly increasing their out-of-pocket expenses.
Furthermore, switching between different estradiol patch products is not always a straightforward solution. Dr. Patil explained to NBC News that some women experience increased menopausal symptoms when switching from a twice-weekly patch to a weekly formulation, indicating that the frequency of application can be crucial for symptom management. Even switching between different brands of the same type of patch can be problematic because the non-drug components, such as adhesives and the matrix releasing the medication, can vary. Clinicians interviewed by NBC News also reported that the shortages appear to be disproportionately affecting twice-weekly patch formulations, which are often preferred by patients.
In response to the widespread access issues, the FDA has provided direct guidance to patients: do not stop or alter hormone therapy without consulting a healthcare provider. This advice is critical, as abrupt discontinuation of hormone therapy can lead to the return of severe menopausal symptoms and is not a safe or effective workaround for an out-of-stock notice.
The agency recommends that patients first contact their pharmacist. Pharmacists are often able to check the availability of the prescribed patch at other locations or may be able to identify an FDA-approved alternative from a different manufacturer that can be substituted, provided it is clinically appropriate. Patients are also encouraged to discuss alternative estradiol products with their prescriber and to periodically check back with their pharmacy as manufacturers gradually increase and release more supply.
For patients who may not be able to access or tolerate patches, other delivery routes for estrogen therapy exist. The American College of Obstetricians and Gynecologists identifies estrogen therapy as the most effective treatment for menopausal symptoms such as hot flashes and night sweats. This therapy is available in various forms, including oral pills, topical gels, injectable medications, and vaginal inserts. Clinicians interviewed by NBC News highlighted that patches are often preferred over oral pills due to a lower associated risk of blood clots, underscoring why a decision to switch to an alternative delivery method should be made in consultation with a healthcare provider, rather than by the patient alone.
The FDA has reiterated its commitment to continuously monitoring the supply of estradiol patches and expediting the review of any submissions aimed at increasing production. The key developments to watch in the coming months will be whether the agency ultimately adds estradiol patches to its official drug shortage database and whether the ASHP’s listings begin to show a decrease in reported shortages. Currently, neither of these potential developments has a published timeline, leaving a degree of uncertainty for both patients and providers.
